[Triton tumor and Von Recklinghausen's disease. Apropos of a case with an ultrastructural study].

G. Monges,J. Hassoun,P. Fabre,M. Chrestian,L. Garbe,H. Payan

Abstract:Tumeur retroperitoneale sarcomateuse: la microscopie electronique met en evidence des cellules presentant une differenciation musculaire striee (tumeur triton, Woodruff 1973)

What problem does this paper attempt to address?

MicroRNAs As Potential Biomarkers for the Diagnosis of Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Qian Zhou,Jian Yin,Yadong Wang,Xinsuo Zhuang,Zhiyang He,Zuobing Chen,Xiaofeng Yang

DOI: https://doi.org/10.7150/ijms.48214

2021-01-01

International Journal of Medical Sciences

Abstract:Background: Traumatic brain injury (TBI) is a sudden trauma on the head, in which severe TBI (sTBI) is usually associated with death and long-term disability. MicroRNAs (miRNAs) are potential biomarkers of diverse diseases, including TBI. However, few systematic reviews and meta-analyses have been conducted to determine the clinical value of miRNAs expression in TBI patients. Methods: We conducted this systematic review and meta-analysis study according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Embase, the Cochrane Library, Web of Science, from inception to August 26, 2020. We included articles written in English that have reported on the diagnostic value of miRNAs expression in TBI patients. We excluded studies that did not provided sufficient information to construct the 2×2 contingency table. Results: Eight studies investigating the diagnostic value of miRNA in TBI were analyzed in this study. The overall sensitivity, specificity and area under the curve (AUC) of miRNAs in diagnosis of TBI were 89% [95% confidence interval (CI): 0.84-0.93], 92% (95% CI 0.82-0.97) and 95% (95% CI 0.93-0.97). We found that panels of multiple miRNAs could improve the diagnostic accuracy of TBI. Samples from blood and brain tissue have significantly enhanced diagnostic accuracy, when compared with saliva. The AUC of miRNAs in severe TBI was 0.97, with 91% sensitivity and 92% specificity. Conclusion: This systematic review and meta-analysis demonstrated that miRNAs could be potential diagnostic markers in TBI patients. MiRNAs detected in blood and brain tissue display high accuracy for TBI diagnosis.
Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature

Jennifer C. Munoz Pareja,Xue Li,Nithya Gandham,Kevin K. Wang,The Pediatric TBI Workgroup,Lauren Lautenslager,Maria Camila Pareja,Prashanth Shanmugham,Shannon Faulkinberry,Suman Ghosh,Maria Kerrigan,Madhuri R. Kashyap

DOI: https://doi.org/10.1016/j.pediatrneurol.2022.03.002

IF: 4.21

2022-05-01

Pediatric Neurology

Abstract:ObjectiveDespite decades of research, outcomes in pediatric traumatic brain injury (pTBI) remain highly variable. Brain biofluid-specific biomarkers from pTBI patients may allow us to diagnose and prognosticate earlier and with a greater degree of accuracy than conventional methods. This manuscript reviews the evidence surrounding current brain-specific biomarkers in pTBI and assess the temporal relationship between the natural history of the traumatic brain injury (TBI) and measured biomarker levels.MethodsA literature search was conducted in the Ovid, PubMed, MEDLINE, and Cochrane databases seeking relevant publications. The study selection and screening process were documented in a PRISMA flow diagram. Extraction forms included developmental stages of patients, type and biofluid source of biomarkers, brain injury type, and other relevant data.ResultsThe search strategy identified 443 articles, of which 150 examining the biomarkers of our interest, were included. The references retrieved were examined thoroughly and discussed at length with a pediatric neurocritical care intensivist specializing in pTBI and a Ph.D. scientist with a high degree of involvement in TBI biomarker research, authoring a vast amount of literature in this field.ConclusionTBI biomarkers might serve as valuable tools in the diagnosis and prognosis of pTBI. However, while each biomarker has its advantages, they are not without limitations, and therefore, further research is critical in pTBI biomarkers.

pediatrics,clinical neurology
Non-invasive fluid biomarkers in the diagnosis of mild traumatic brain injury (mTBI): a systematic review

Charles Feinberg,Katherine Dickerson Mayes,Ellie Portman,Catherine Carr,Rebekah Mannix

DOI: https://doi.org/10.1136/jnnp-2023-331220

2024-01-11

Abstract:Background: Despite approximately 55.9 million annual mild traumatic brain injuries (mTBIs) worldwide, the accurate diagnosis of mTBI continues to challenge clinicians due to symptom ambiguity, reliance on subjective report and presentation variability. Non-invasive fluid biomarkers of mTBI offer a biological measure to diagnose and monitor mTBI without the need for blood draws or neuroimaging. The objective of this study is to systematically review the utility of such biomarkers to diagnose mTBI and predict disease progression. Methods: A systematic review performed in PubMed, Scopus, Cochrane and Web of Science followed by a manual search of references without a specified timeframe. Search strings were generated and run (27 June 2022) by a research librarian. Studies were included if they: (1) included human mTBI subjects, (2) assessed utility of a non-invasive biomarker and (3) published in English. Exclusion criteria were (1) non-mTBI subjects, (2) mTBI not assessed separately from moderate/severe TBI, (3) required intracranial haemorrhage or (4) solely assesses genetic susceptibility to mTBI. Results: A total of 29 studies from 27 subject populations (1268 mTBI subjects) passed the inclusion and exclusion criteria. Twelve biomarkers were studied. Salivary RNAs, including microRNA, were assessed in 11 studies. Cortisol and melatonin were assessed in four and three studies, respectively. Eight salivary and two urinary biomarkers contained diagnostic or disease monitoring capability. Discussion: This systematic review identified several salivary and urinary biomarkers that demonstrate the potential to be used as a diagnostic, prognostic and monitoring tool for mTBI. Further research should examine miRNA-based models for diagnostic and predictive utility in patients with mTBI. Prospero registration number: CRD42022329293.
Blood Biomarkers for the Management of Mild Traumatic Brain Injury in Clinical Practice

Charlotte Oris,Samy Kahouadji,Damien Bouvier,Vincent Sapin

DOI: https://doi.org/10.1093/clinchem/hvae049

IF: 12.114

2024-04-24

Clinical Chemistry

Abstract:Abstract Background Despite the use of validated guidelines in the management of mild traumatic brain injury (mTBI), processes to limit unnecessary brain scans are still not sufficient and need to be improved. The use of blood biomarkers represents a relevant adjunct to identify patients at risk for intracranial injury requiring computed tomography (CT) scan. Content Biomarkers currently recommended in the management of mTBI in adults and children are discussed in this review. Protein S100 beta (S100B) is the best-documented blood biomarker due to its validation in large observational and interventional studies. Glial fibrillary acidic protein (GFAP) and ubiquitin carboxyterminal hydrolase L-1 (UCH-L1) have also recently demonstrated their usefulness in patients with mTBI. Preanalytical, analytical, and postanalytical performance are presented to aid in their interpretation in clinical practice. Finally, new perspectives on biomarkers and mTBI are discussed. Summary In adults, the inclusion of S100B in Scandinavian and French guidelines has reduced the need for CT scans by at least 30%. S100B has significant potential as a diagnostic biomarker, but limitations include its rapid half-life, which requires blood collection within 3 h of trauma, and its lack of neurospecificity. In 2018, the FDA approved the use of combined determination of GFAP and UCH-L1 to aid in the assessment of mTBI. Since 2022, new French guidelines also recommend the determination of GFAP and UCH-L1 in order to target a larger number of patients (sampling within 12 h post-injury) and optimize the reduction of CT scans. In the future, new cut-offs related to age and promising new biomarkers are expected for both diagnostic and prognostic applications.

medical laboratory technology
Biofluid biomarkers of traumatic brain injury

Denes V Agoston,Andrew Shutes-David,Elaine R Peskind

DOI: https://doi.org/10.1080/02699052.2017.1357836

2017-07-29

Brain Injury

Abstract:PRIMARY OBJECTIVE: The purpose of this paper is to review the clinical and research utility and applications of blood, cerebrospinal fluid (CSF), and cerebral microdialysis biomarkers in traumatic brain injury (TBI).RESEARCH DESIGN: Not applicable.METHODS AND PROCEDURES: A selective review was performed on these biofluid biomarkers in TBI.MAIN OUTCOME AND RESULTS: Neurofilament heavy chain protein (NF-H), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCHL1), neuron-specific enolase (NSE), myelin basic protein (MBP), tau, and s100β blood biomarkers are elevated during the acute phase of severe head trauma but have key limitations in their research and clinical applications to mild TBI (mTBI). CSF biomarkers currently provide the best reflection of the central nervous system (CNS) pathobiological processes in TBI. Both animal and human studies of TBI have demonstrated the importance of serial sampling of biofluids and suggest that CSF biomarkers may be better equipped to characterize both TBI severity and temporal profiles.CONCLUSIONS: The identification of biofluid biomarkers could play a vital role in identifying, diagnosing, and treating the underlying individual pathobiological changes of TBI. CNS-derived exosomes analyzed by ultra-high sensitivity detection methods have the potential to identify blood biomarkers for the range of TBI severity and time course.

neurosciences,rehabilitation
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues

Daniel B. Hier,Tayo Obafemi-Ajayi,Matthew S. Thimgan,Gayla R. Olbricht,Sima Azizi,Blaine Allen,Bassam A. Hadi,Donald C. Wunsch

DOI: https://doi.org/10.1186/s40364-021-00325-5

2021-09-16

Biomarker Research

Abstract:Abstract Background The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neurofilament light chain, ubiquitin carboxy-terminal hydrolase-L1, tau, S100B, and glial acidic fibrillary protein. We conducted a focused literature review of unresolved issues in three areas: mode of entry into and exit from the blood, kinetics of blood biomarkers in the blood, and predictive capacity of the blood biomarkers after mTBI. Findings Although a disruption of the blood brain barrier has been demonstrated in mild and severe traumatic brain injury, biomarkers can enter the blood through pathways that do not require a breach in this barrier. A definitive accounting for the pathways that biomarkers follow from the brain to the blood after mTBI has not been performed. Although preliminary investigations of blood biomarkers kinetics after TBI are available, our current knowledge is incomplete and definitive studies are needed. Optimal sampling times for biomarkers after mTBI have not been established. Kinetic models of blood biomarkers can be informative, but more precise estimates of kinetic parameters are needed. Confounding factors for blood biomarker levels have been identified, but corrections for these factors are not routinely made. Little evidence has emerged to date to suggest that blood biomarker levels correlate with clinical measures of mTBI severity. The significance of elevated biomarker levels thirty or more days following mTBI is uncertain. Blood biomarkers have shown a modest but not definitive ability to distinguish concussed from non-concussed subjects, to detect sub-concussive hits to the head, and to predict recovery from mTBI. Blood biomarkers have performed best at distinguishing CT scan positive from CT scan negative subjects after mTBI.

oncology,medicine, research & experimental
Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury

Stefania Mondello,Firas Kobeissy,Annarita Vestri,Ronald L. Hayes,Patrick M. Kochanek,Rachel P. Berger

DOI: https://doi.org/10.1038/srep28203

IF: 4.6

2016-06-01

Scientific Reports

Abstract:Objective reliable markers to assess traumatic brain injury (TBI) and predict outcome soon after injury are a highly needed tool for optimizing management of pediatric TBI. We assessed serum concentrations of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in a cohort of 45 children with clinical diagnosis of TBI (Glasgow Coma Scale [GCS] 3–15) and 40 healthy subjects, evaluated their associations with clinical characteristics and outcomes, and compared their performance to previously published data on two well-studied blood biomarkers, S100B and MBP. We observed higher serum levels of GFAP and UCH-L1 in brain-injured children compared with controls and also demonstrated a step-wise increase of biomarker concentrations over the continuum of severity from mild to severe TBI. Furthermore, while we found that only the neuronal biomarker UCH-L1 holds potential to detect acute intracranial lesions as assessed by computed tomography (CT), both markers were substantially increased in TBI patients even with a normal CT suggesting the presence of undetected microstructural injuries. Serum UCH-L1 and GFAP concentrations also strongly predicted poor outcome and performed better than S100B and MBP. Our results point to a role of GFAP and UCH-L1 as candidate biomarkers for pediatric TBI. Further studies are warranted.

multidisciplinary sciences
Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury

Georgene W. Hergenroeder,John B. Redell,Anthony N. Moore,Pramod K. Dash

DOI: https://doi.org/10.1007/bf03256301

2008-11-01

Abstract:Traumatic brain injury (TBI) is the leading cause of death and disability among young adults. Numerous safety improvements in the workplace, the addition of airbags to vehicles, and the enforcement of speed limits have all helped to reduce the incidence and severity of head trauma. While improvements in emergency response times and acute care have increased TBI survivability, this has heightened the necessity for developing reliable methods to identify patients at risk of developing secondary pathologies. At present, the primary clinical indicators for the presence of brain injury are the Glasgow Coma Scale (GCS), pupil reactivity, and head computed tomography (CT). While these indices have proven useful for stratifying the magnitude and extent of brain damage, they have limited utility for predicting adverse secondary events or detecting subtle damage. Biomarkers, reflecting a biological response to injury or disease, have proven useful for the diagnosis of many pathological conditions including cancer, heart failure, infection, and genetic disorders. For TBI, several proteins synthesized in astroglial cells or neurons have been proposed as potential biomarkers. These proteins include the BB isozyme of creatine kinase (CK-BB, predominant in brain), glial fibrilary acidic protein (GFAP), myelin basic protein (MBP), neuron-specific enolase (NSE), and S100B.The presence of these biomarkers in the cerebrospinal fluid and serum of patients with moderate-to-severe TBI, and their correlation with outcome, suggest that they may have utility as surrogate markers in clinical trials. In addition, many of these markers have been found to be sensitive indicators of injury, and therefore may have the potential to diagnose persons with mild TBI. In addition to biomarkers that correlate with long-term outcome, a few studies have identified prognostic biomarkers for secondary injury that may be useful in individualizing patient management.

pharmacology & pharmacy,genetics & heredity
Effects of age and time since injury on traumatic brain injury blood biomarkers: a TRACK-TBI study

Raquel C Gardner,Ava M Puccio,Frederick K Korley,Kevin K W Wang,Ramon Diaz-Arrastia,David O Okonkwo,Ross C Puffer,Esther L Yuh,John K Yue,Xiaoying Sun,Sabrina R Taylor,Pratik Mukherjee,Sonia Jain,Geoffrey T Manley,Venkata R Feeser,Adam R Ferguson,Etienne Gaudette,Shankar Gopinath,C Dirk Keene,Christopher Madden,Alastair Martin,Michael McCrea,Randall Merchant,Pratik Mukherjee,Laura B Ngwenya,Claudia Robertson,Nancy Temkin,Mary Vassar,John K Yue,Ross Zafonte,

DOI: https://doi.org/10.1093/braincomms/fcac316

2022-12-01

Brain Communications

Abstract:Abstract Older adults have the highest incidence of traumatic brain injury globally. Accurate blood-based biomarkers are needed to assist with diagnosis of patients across the spectrum of age and time post-injury. Several reports have suggested lower accuracy for blood-based biomarkers in older adults, and there is a paucity of data beyond day-1 post-injury. Our aims were to investigate age-related differences in diagnostic accuracy and 2-week evolution of four leading candidate blood-based traumatic brain injury biomarkers—plasma glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, S100 calcium binding protein B and neuron-specific enolase—among participants in the 18-site prospective cohort study Transforming Research And Clinical Knowledge in Traumatic Brain Injury. Day-1 biomarker data were available for 2602 participants including 2151 patients with traumatic brain injury, 242 orthopedic trauma controls and 209 healthy controls. Participants were stratified into 3 age categories (young: 17–39 years, middle-aged: 40–64 years, older: 65–90 years). We investigated age-stratified biomarker levels and biomarker discriminative abilities across three diagnostic groups: head CT-positive/negative; traumatic brain injury/orthopedic controls; and traumatic brain injury/healthy controls. The difference in day-1 glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1 and neuron-specific enolase levels across most diagnostic groups was significantly smaller for older versus younger adults, resulting in a narrower range within which a traumatic brain injury diagnosis may be discriminated in older adults. Despite this, day-1 glial fibrillary acidic protein had good to excellent performance across all age-categories for discriminating all three diagnostic groups (area under the curve 0.84–0.96; lower limit of 95% confidence intervals all >0.78). Day-1 S100 calcium-binding protein B and ubiquitin carboxy-terminal hydrolase L1 showed good discrimination of CT-positive versus negative only among adults under age 40 years within 6 hours of injury. Longitudinal blood-based biomarker data were available for 522 hospitalized patients with traumatic brain injury and 24 hospitalized orthopaedic controls. Glial fibrillary acidic protein levels maintained good to excellent discrimination across diagnostic groups until day 3 post-injury irrespective of age, until day 5 post-injury among middle-aged or younger patients and until week 2 post-injury among young patients only. In conclusion, the blood-based glial fibrillary acidic protein assay tested here has good to excellent performance across all age-categories for discriminating key traumatic brain injury diagnostic groups to at least 3 days post-injury in this trauma centre cohort. The addition of a blood-based diagnostic to the evaluation of traumatic brain injury, including geriatric traumatic brain injury, has potential to streamline diagnosis.
Benefits of Building Information Modeling Relative to Medical Gas Systems in Healthcare Construction

J. Abeln,K. Rahn,S. Kramer

Abstract:This research explores the potential benefits and challenges of utilizing integrated Building Information Modeling (BIM) for the planning, coordination, and installation of medical gas systems within healthcare construction. In other words, what are the quality, cost, and schedule benefits associated with implementing BIM during the design and construction life cycle of medical gas systems? Research collected from a large healthcare facility project confirms that the inclusion of BIM directly relates to improved quality, decreased installation duration, and increased trade specific profit. Along with the confirmation of these results, additional cost considerations relative to BIM were identified concerning the ease and efficiency with which project materials are estimated. The relevant challenges associated with BIM were also explored as lessons learned for future projects.
Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-21

T. Vorup-Jensen,S. Petersen,A. Hansen,K. Poulsen,W. Schwaeble,Robert B Sim,K. Reid,S. Davis,S. Thiel,J. Jensenius

DOI: https://doi.org/10.4049/jimmunol.165.4.2093

2000-08-15

Abstract:Mannan-binding lectin (MBL) plays a pivotal role in innate immunity by activating complement after binding carbohydrate moieties on pathogenic bacteria and viruses. Structural similarities shared by MBL and C1 complexes and by the MBL- and C1q-associated serine proteases, MBL-associated serine protease (MASP)-1 and MASP-2, and C1r and C1s, respectively, have led to the expectation that the pathways of complement activation by MBL and C1 complexes are likely to be very similar. We have expressed rMASP-2 and show that, whereas C1 complex autoactivation proceeds via a two-step mechanism requiring proteolytic activation of both C1r and C1s, reconstitution with MASP-2 alone is sufficient for complement activation by MBL. The results suggest that the catalytic activities of MASP-2 split between the two proteases of the C1 complex during the course of vertebrate complement evolution.
Brain biomarkers and pre-injury cognition are associated with long-term cognitive outcome in children with traumatic brain injury

Amy A. Wilkinson,Maureen Dennis,Nevena Simic,Margot J. Taylor,Benjamin R. Morgan,Helena Frndova,Karen Choong,Craig Campbell,Douglas Fraser,Vicki Anderson,Anne-Marie Guerguerian,Russell Schachar,Jamie Hutchison,For the Canadian Critical Care Trials Group (CCCTG),The Canadian Critical Care Translational Biology Group (CCCTBG),,

DOI: https://doi.org/10.1186/s12887-017-0925-6

2017-07-24

BMC Pediatrics

Abstract:BackgroundChildren with traumatic brain injury (TBI) are frequently at risk of long-term impairments of attention and executive functioning but these problems are difficult to predict. Although deficits have been reported to vary with injury severity, age at injury and sex, prognostication of outcome remains imperfect at a patient-specific level. The objective of this proof of principle study was to evaluate a variety of patient variables, along with six brain-specific and inflammatory serum protein biomarkers, as predictors of long-term cognitive outcome following paediatric TBI.MethodOutcome was assessed in 23 patients via parent-rated questionnaires related to attention deficit hyperactivity disorder (ADHD) and executive functioning, using the Conners 3rd Edition Rating Scales (Conners-3) and Behaviour Rating Inventory of Executive Function (BRIEF) at a mean time since injury of 3.1 years. Partial least squares (PLS) analyses were performed to identify factors measured at the time of injury that were most closely associated with outcome on (1) the Conners-3 and (2) the Behavioural Regulation Index (BRI) and (3) Metacognition Index (MI) of the BRIEF.ResultsHigher levels of neuron specific enolase (NSE) and lower levels of soluble neuron cell adhesion molecule (sNCAM) were associated with higher scores on the inattention, hyperactivity/impulsivity and executive functioning scales of the Conners-3, as well as working memory and initiate scales of the MI from the BRIEF. Higher levels of NSE only were associated with higher scores on the inhibit scale of the BRI.ConclusionsNSE and sNCAM show promise as reliable, early predictors of long-term attention-related and executive functioning problems following paediatric TBI.

pediatrics
Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature

Carlos A. Santacruz,Jean-Louis Vincent,Andres Bader,Luis A. Rincón-Gutiérrez,Claudia Dominguez-Curell,David Communi,Fabio S. Taccone

DOI: https://doi.org/10.1186/s13054-021-03698-z

IF: 15.1

2021-08-05

Critical Care

Abstract:Abstract Background Acute brain injuries are associated with high mortality rates and poor long-term functional outcomes. Measurement of cerebrospinal fluid (CSF) biomarkers in patients with acute brain injuries may help elucidate some of the pathophysiological pathways involved in the prognosis of these patients. Methods We performed a systematic search and descriptive review using the MEDLINE database and the PubMed interface from inception up to June 29, 2021, to retrieve observational studies in which the relationship between CSF concentrations of protein biomarkers and neurological outcomes was reported in patients with acute brain injury [traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, status epilepticus or post-cardiac arrest]. We classified the studies according to whether or not biomarker concentrations were associated with neurological outcomes. The methodological quality of the studies was evaluated using the Newcastle–Ottawa quality assessment scale. Results Of the 39 studies that met our criteria, 30 reported that the biomarker concentration was associated with neurological outcome and 9 reported no association. In TBI, increased extracellular concentrations of biomarkers related to neuronal cytoskeletal disruption, apoptosis and inflammation were associated with the severity of acute brain injury, early mortality and worse long-term functional outcome. Reduced concentrations of protein biomarkers related to impaired redox function were associated with increased risk of neurological deficit. In non-traumatic acute brain injury, concentrations of CSF protein biomarkers related to dysregulated inflammation and apoptosis were associated with a greater risk of vasospasm and a larger volume of brain ischemia. There was a high risk of bias across the studies. Conclusion In patients with acute brain injury, altered CSF concentrations of protein biomarkers related to cytoskeletal damage, inflammation, apoptosis and oxidative stress may be predictive of worse neurological outcomes.

critical care medicine
Fluid biomarkers of chronic traumatic brain injury

Susanna Friberg,Caroline Lindblad,Frederick A. Zeiler,Henrik Zetterberg,Tobias Granberg,Per Svenningsson,Fredrik Piehl,Eric P. Thelin

DOI: https://doi.org/10.1038/s41582-024-01024-z

IF: 38.1

2024-10-04

Nature Reviews Neurology

Abstract:Traumatic brain injury (TBI) is a leading cause of long-term disability across the world. Evidence for the usefulness of imaging and fluid biomarkers to predict outcomes and screen for the need to monitor complications in the acute stage is steadily increasing. Still, many people experience symptoms such as fatigue and cognitive and motor dysfunction in the chronic phase of TBI, where objective assessments for brain injury are lacking. Consensus criteria for traumatic encephalopathy syndrome, a clinical syndrome possibly associated with the neurodegenerative disease chronic traumatic encephalopathy, which is commonly associated with sports concussion, have been defined only recently. However, these criteria do not fit all individuals living with chronic consequences of TBI. The pathophysiology of chronic TBI shares many similarities with other neurodegenerative and neuroinflammatory conditions, such as Alzheimer disease. As with Alzheimer disease, advancements in fluid biomarkers represent one of the most promising paths for unravelling the chain of pathophysiological events to enable discrimination between these conditions and, with time, provide prediction modelling and therapeutic end points. This Review summarizes fluid biomarker findings in the chronic phase of TBI (≥6 months after injury) that demonstrate the involvement of inflammation, glial biology and neurodegeneration in the long-term complications of TBI. We explore how the biomarkers associate with outcome and imaging findings and aim to establish mechanistic differences in biomarker patterns between types of chronic TBI and other neurodegenerative conditions. Finally, current limitations and areas of priority for future fluid biomarker research are highlighted.

clinical neurology
Blood‐based biomarkers and traumatic brain injury—A clinical perspective

Jussi P. Posti,Olli Tenovuo

DOI: https://doi.org/10.1111/ane.13620

2022-04-05

Acta Neurologica Scandinavica

Abstract:Blood‐based biomarkers are promising tools to complement clinical variables and imaging findings in the diagnosis, monitoring and outcome prediction of traumatic brain injury (TBI). Several promising biomarker candidates have been found for various clinical questions, but the translation of TBI biomarkers into clinical applications has been negligible. Measured biomarker levels are influenced by patient‐related variables such as age, blood‐brain barrier integrity and renal and liver function. It is not yet fully understood how biomarkers enter the bloodstream from the interstitial fluid of the brain. In addition, the diagnostic performance of TBI biomarkers is affected by sampling timing and analytical methods. In this focused review, the clinical aspects of glial fibrillary acidic protein, neurofilament light, S100 calcium‐binding protein B, tau and ubiquitin C‐terminal hydrolase‐L1 are examined. Current findings and clinical caveats are addressed.

clinical neurology
Effect of immune sera on proliferative activity of L cell cultures

A. V. Simonova,V. V. Khorobrykh,K. A. Lebedev

DOI: https://doi.org/10.1007/BF00829548

IF: 0.737

Bulletin of Experimental Biology and Medicine

Abstract:
Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury

Robert D. Welch,Syed I. Ayaz,Lawrence M. Lewis,Johan Unden,James Y. Chen,Valerie H. Mika,Ben Saville,Joseph A. Tyndall,Marshall Nash,Andras Buki,Pal Barzo,Dallas Hack,Frank C. Tortella,Kara Schmid,Ronald L. Hayes,Arastoo Vossough,Stephen T. Sweriduk,Jeffrey J. Bazarian

DOI: https://doi.org/10.1089/neu.2015.4149

IF: 4.869

2016-01-15

Journal of Neurotrauma

Abstract:Head computed tomography (CT) imaging is still a commonly obtained diagnostic test for patients with minor head injury despite availability of clinical decision rules to guide imaging use and recommendations to reduce radiation exposure resulting from unnecessary imaging. This prospective multicenter observational study of 251 patients with suspected mild to moderate traumatic brain injury (TBI) evaluated three serum biomarkers' (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6 h of injury) ability to differentiate CT negative and CT positive findings. Of the 251 patients, 60.2% were male and 225 (89.6%) had a presenting Glasgow Coma Scale score of 15. A positive head CT (intracranial injury) was found in 36 (14.3%). UCH-L1 was 100% sensitive and 39% specific at a cutoff value >40 pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0 pg/mL) and S100B had a specificity of only 2% (cutoff value 30 pg/mL). All three biomarkers had similar values for areas under the receiver operator characteristic curve: 0.79 (95% confidence interval; 0.70-0.88) for GFAP, 0.80 (0.71-0.89) for UCH-L1, and 0.75 (0.65-0.85) for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B (p = 0.21 and p = 0.77, respectively). In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT use without sacrificing sensitivity. UCH-L1 values <40 pg/mL could potentially have aided in eliminating 83 of the 215 negative CT scans. These results require replication in other studies before the test is used in actual clinical practice.

neurosciences,clinical neurology,critical care medicine
[Comparative study of suicide attempts by children and adolescents observed in 3 pediatric departments and those collected in a pedo-psychiatric department].

M. Moch

1969-08-01

Abstract:
Update on the role of S100B in traumatic brain injury in pediatric population: a meta-analysis

Alberto Morello,Irene Schiavetti,Enrico Lo Bue,Irene Portonero,Stefano Colonna,Andrea Gatto,Marco Pavanello,Michele Maria Lanotte,Diego Garbossa,Fabio Cofano

DOI: https://doi.org/10.1007/s00381-024-06565-8

2024-08-23

Abstract:Abstract Objective Cranial computed tomography (CT) scan is the most widely used tool to rule out intracranial lesions after pediatric traumatic brain injury (TBI). However, in pediatric population, the radiation exposure can lead to an increased risk of hematological and brain neoplasm. Defined in 2019 National Institute for Health and Care Excellence (NICE) guidelines as “troponins for the brain”, serum biomarkers measurements, particularly S100B, have progressively emerged as a supplementary tool in the management of TBI thanks to their capacity to predict intracranial post-traumatic lesions. Methods This systematic review was conducted following the PRISMA protocol (preferred reporting items for systematic reviews and meta-analyses). No chronological limits of study publications were included. Studies reporting data from children with TBI undergoing serum S100B measurement and computed tomography (CT) scans were included. Results Of 380 articles screened, 10 studies met the inclusion criteria. Patients admitted with mild-TBI in the Emergency Department (ED) were 1325 (80.25%). The overall pooled sensitivity and specificity were 98% (95% CI, 92–99%) and 45% (95% CI, 29–63%), respectively. The meta-analysis revealed a high negative predictive value (NVP) (99%; 95% CI, 94–100%) and a low positive predictive value (PPV) (41%; 95% CI, 16–79%). Area under the curve (AUC) was 76% (95% CI, 65–85%). The overall pooled negative predictive value (NPV) was 99% (95% CI, 99–100%). Conclusions The measurement of serum S100B in the diagnostic workflow of mTBI could help informed decision-making in the ED setting, potentially safely reducing the use of CT scan in the pediatric population. The high sensitivity and excellent negative predictive values look promising and seem to be close to the values found in adults. Despite this, it must be pointed out the high heterogeneity (> 90%) found among studies. In order for S100B to be regularly introduced in the pediatric workflow for TBI, it is important to conduct further studies to obtain cut-off levels based on pediatric reference intervals.

pediatrics,surgery,clinical neurology
Panel of serum protein biomarkers to grade the severity of traumatic brain injury

Raj Poovindran Anada,Kum Thong Wong,Jaime Jacqueline Jayapalan,Onn Haji Hashim,Dharmendra Ganesan

DOI: https://doi.org/10.1002/elps.201700407

2018-04-25

Electrophoresis

Abstract:The Glasgow Coma Scale (GCS), which classifies patients into mild, moderate or severe traumatic brain injury (TBI), is a system used to prioritize treatment and prognosticate the severity of head injury. In this study, sera of patients with various stages of TBI, as well as control subjects, were analyzed to screen for proteins that may be used to complement the GCS system. By subjecting pooled serum samples to iTRAQ analysis for quantitative comparison of protein abundance, and attesting their altered levels using ELISA, we have detected increased levels of serum amyloid A, C-reactive protein, leucine-rich alpha-2-glycoprotein, lipopolysaccharide-binding protein, fibronectin, vitronectin and alpha-1-antichymotrypsin in patients across all strata of TBI relative to the controls. However, kininogen was decreased only in moderate and severe TBI, whereas apolipoprotein E and zinc-alpha-2-glycoprotein were only increased in severe TBI. Hence, we propose a panel of serum biomarkers, which if analyzed within 24 h of the injury, can be used to diagnose patients with TBI into mild, moderate or severe stratification objectively, thus complementing the traditional GCS.

biochemical research methods,chemistry, analytical

[Triton tumor and Von Recklinghausen's disease. Apropos of a case with an ultrastructural study].

MicroRNAs As Potential Biomarkers for the Diagnosis of Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature

Non-invasive fluid biomarkers in the diagnosis of mild traumatic brain injury (mTBI): a systematic review

Blood Biomarkers for the Management of Mild Traumatic Brain Injury in Clinical Practice

Biofluid biomarkers of traumatic brain injury

Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues

Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury

Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury

Effects of age and time since injury on traumatic brain injury blood biomarkers: a TRACK-TBI study

Benefits of Building Information Modeling Relative to Medical Gas Systems in Healthcare Construction

Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-21

Brain biomarkers and pre-injury cognition are associated with long-term cognitive outcome in children with traumatic brain injury

Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature

Fluid biomarkers of chronic traumatic brain injury

Blood‐based biomarkers and traumatic brain injury—A clinical perspective

Effect of immune sera on proliferative activity of L cell cultures

Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury

[Comparative study of suicide attempts by children and adolescents observed in 3 pediatric departments and those collected in a pedo-psychiatric department].

Update on the role of S100B in traumatic brain injury in pediatric population: a meta-analysis

Panel of serum protein biomarkers to grade the severity of traumatic brain injury